Novast Holdings
Novast is focused on the research, development and manufacture of value-added generic drugs.
Business Model:
Revenue: $0
Employees: 51-500
Industries / Tags:
Detailed Novast Holdings Information
Geographic Data
Address:
City: Nantong
State: Jiangsu
Zip:
Country: China
Financial Info
Stage:
series unknown
Raised Last:
$62M
Raised Total:$303M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2021 | Venture Round | 2 | $62.2M |
Highlight Capital Shiyu Ziben Highlight Capital Shiyu Ziben |
5/2020 | Venture Round | $0 |
Highlight Capital Legend Capital Shiyu Capital Xiamen C&a;D Corporation Highlight Capital Legend Capital Shiyu Capital Xiamen C&a;D Corporation |
10/2008 | Series B | 2 | $50M |
New Enterprise Associates Qiming Venture Partners New Enterprise Associates Qiming Venture Partners |
6/2009 | Series B | 3 | $25M |
New Enterprise Associates Qiming Venture Partners SAIF Partners New Enterprise Associates Qiming Venture Partners SAIF Partners |
6/2011 | Series C | 1 | $2.9M |
Qiming Venture Partners Qiming Venture Partners |
6/2012 | Corporate Round | 1 | $20M |
Eli Lilly Eli Lilly |
9/2011 | Series D | 1 | $2M |
Qiming Venture Partners Qiming Venture Partners |
5/2020 | Venture Round | 4 | $141.2M |
Highlight Capital Legend Capital Shiyu Capital Xiamen C&a;D Corporation Highlight Capital Legend Capital Shiyu Capital Xiamen C&a;D Corporation |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
